Showing results (151-160 of 173) with videos related to

Sort By:
Pageof 18
Respirology (Carlton, Vic.)|November 29, 2022
Predictive value of serum high-mobility group box 1 levels for checkpoint inhibitor pneumonitisHiroki Tanahashi, Kakuhiro Yamaguchi, Koji Kurose, et al.
International Journal of Clinical Oncology|September 19, 2019
Albumin-globulin ratio is a predictive biomarker of antitumor effect of anti-PD-1 antibody in patients with non-small cell lung cancerYu Nakanishi, Takeshi Masuda, Kakuhiro Yamaguchi, et al.
Internal Medicine (Tokyo, Japan)|August 10, 2021
Pulmonary Alveolar Proteinosis with Severe Respiratory Failure Improved by Segmental Lung Lavage with Fiberoptic Bronchoscopy under General AnesthesiaYu Matsumoto, Takeshi Masuda, Tatsuki Takahashi, et al.
Respiratory Investigation|August 9, 2020
Extent of pulmonary fibrosis on high-resolution computed tomography is a prognostic factor in patients with pleuroparenchymal fibroelastosisMasashi Namba, Takeshi Masuda, Shun Takao, et al.
The Journal of Asthma : Official Journal of the Association for the Care of Asthma|March 30, 2021
Vocal cord dysfunction detected by a three-dimensional image of dynamic change in respiratory resistance in a patient with difficult-to-treat asthma: a case reportAyaka Oda, Toshihito Otani, Hiroshi Iwamoto, et al.
JAMA Network Open|November 12, 2020
Association of Preexisting Interstitial Lung Abnormalities With Immune Checkpoint Inhibitor-Induced Interstitial Lung Disease Among Patients With Nonlung CancersKiyofumi Shimoji, Takeshi Masuda, Kakuhiro Yamaguchi, et al.
The European Respiratory Journal|March 10, 2018
Aminopeptidase N/CD13 as a potential therapeutic target in malignant pleural mesotheliomaTakahiko Otsuki, Taku Nakashima, Hironobu Hamada, et al.
Cancer Science|October 26, 2020
Clinical significance of BIM deletion polymorphism in chemoradiotherapy for non-small cell lung cancerYu Wakabayashi, Takeshi Masuda, Kazunori Fujitaka, et al.
Anticancer Research|May 6, 2021
Prognostic Significance of <i>EGFR</i> Gene Mutation in Patients With EGFR Mutated Non-small Cell Lung Cancer Who Received Best Supportive Care AloneTakeshi Masuda, Y U Wakabayashi, Taku Nakashima, et al.
In Vivo (Athens, Greece)|August 29, 2018
Bevacizumab with Single-agent Chemotherapy in Previously Treated Non-squamous Non-small-cell Lung Cancer: Phase II StudyKakuhiro Yamaguchi, Takeshi Masuda, Kazunori Fujitaka, et al.
Pageof 18